Careers

A New Hope in the Battle Against Fatty Liver Disease: Understanding Rezdiffra™ (resmetirom)

A New Hope in the Battle Against Fatty Liver Disease: Understanding Rezdiffra™ (resmetirom)

March 14, 2024 | By | Clinical Research, Clinical Trials, Liver, Liver Disease, Liver Health, NASH, News & Events

Today, we’re talking about some exciting news for people battling fatty liver disease, specifically Nonalcoholic Steatohepatitis (NASH) a condition where too much fat is stored in the liver, causing inflammation and damage. NASH is a tricky disease because it’s often …

Rezdiffra™ (resmetirom) and NASH: A Promising Advance in Treatment

Rezdiffra™ (resmetirom) and NASH: A Promising Advance in Treatment

March 14, 2024 | By | News & Events, Clinical Trials, Liver, Liver Disease, Liver Health, NASH | Promising Advance in Treatment, resmetirom, Rezdiffra

Nonalcoholic Steatohepatitis (NASH) (now known as Metabolic Dysfunction-Associated Steatohepatitis or MASH) represents a significant and growing challenge in clinical practice, with its progression to cirrhosis and hepatocellular carcinoma posing serious risks for patients. The exciting new conditional commercial launch of …